Altunbulakli C, Costa R, Lan F, Zhang N, Akdis M, Bachert C, Akdis CA
SURMOUNT OSA demonstrated after 52 weeks of treatment, participants who received tirzepatide had greater likelihood of remission or improvement to mild OSA as well as reduced apnea-hypopnea index (AHI) values, hypoxic burden, and systolic blood pressure
GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well
These include: Individuals with a history of pancreatitis: Due to the risk of recurrent episodes
Gender differences also played a role, with men 12% more likely to discontinue treatment than women